Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P19544
UPID:
WT1_HUMAN
Alternative names:
WT33
Alternative UPACC:
P19544; A8K6S1; B3KSA5; Q15881; Q16256; Q16575; Q4VXV4; Q4VXV5; Q4VXV6; Q8IYZ5
Background:
The Wilms tumor protein (WT33) is a pivotal transcription factor involved in cellular development and survival. It binds to specific DNA sequences, regulating the expression of target genes such as EPO, and plays a crucial role in the development of the urogenital system. Its function varies by isoform, with some acting as transcription factors and others involved in mRNA metabolism or splicing.
Therapeutic significance:
WT33 is linked to several diseases, including Frasier syndrome, Wilms tumor 1, Denys-Drash syndrome, Nephrotic syndrome 4, Meacham syndrome, and malignant Mesothelioma. Its dual role as a tumor suppressor and oncogene highlights its potential as a target for therapeutic strategies in these conditions.